Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications

详细信息    查看全文

• 作者：Melinda Liu ; Yuan Yu M. Huang ; Sylvia Hsu ; Joseph S. Kass
• 刊名：CNS Drugs
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：30
• 期：12
• 页码：1149-1168
• 全文大小：
• 刊物主题：Neurology; Psychopharmacology; Pharmacotherapy; Neurosciences; Psychiatry;
• 出版者：Springer International Publishing
• ISSN：1179-1934
• 卷排序：30

文摘

Severe, recalcitrant dermatologic conditions often require systemic treatment. Although efficacious, these medications have been associated with wide-ranging adverse reactions. Some are reversible, predictable, and either dose-dependent or treatment length-dependent, while others are unpredictable, irreversible, and potentially fatal. This review examines the neuropsychiatric adverse effects associated with US FDA-approved medications for treatment of the following dermatologic pathologies that typically require systemic therapy: autoimmune dermatoses, acne, psoriasis, and melanoma. A search of the literature was performed, with adverse effects ranging from mild headaches and neuropathy to severe encephalopathies. The medications associated with the most serious reactions were those used to treat psoriasis, especially the older non-biologic medications such as cyclosporine A and methotrexate. Given the importance of these systemic dermatologic therapies in treating severe, recalcitrant conditions, and the wide variety of potentially serious neuropsychiatric adverse effects of these medications, neurologists, psychiatrists, dermatologists, oncologists, and primary care providers must be aware of the potential for these neuropsychiatric adverse reactions to allow for appropriate counseling, management, and medication withdrawal.